NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types

Use of PET is widespread and increasing in the United States, mainly for oncologic applications. In November 2006, the National Comprehensive Cancer Network (NCCN) gathered a panel of experts to review the literature and develop clinical recommendations for using PET scans in lymphoma and non–small cell lung, breast, and colorectal cancers. However, because its use is not restricted to these diseases, and evidence is accumulating for its application in other types of cancers, NCCN convened a second meeting in December 2008 to expand on the initial report. A multidisciplinary panel met to discuss the current data on PET application for various tumor types, including genitourinary, gynecologic, pancreatic, hepatobiliary, thyroid, brain, small cell lung, gastric, and esophageal cancers, and sarcoma and myeloma. This report summarizes the proceedings of this meeting, including discussions of the background of PET, the role of PET in oncology, principles of PET use, emerging applications, and possible future developments.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Podoloff DA, Advani RH, Allred C. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5(Suppl 1):S122; quiz S23–22.

    • Search Google Scholar
    • Export Citation
  • 2

    Casneuf V, Delrue L, Kelles A. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg 2007;70:331338.

    • Search Google Scholar
    • Export Citation
  • 3

    Dirisamer A, Halpern BS, Flory D. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT. Eur J Radiol 2009; in press.

    • Search Google Scholar
    • Export Citation
  • 4

    Gerth HU, Juergens KU, Dirksen U. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med 2007;48:19321939.

    • Search Google Scholar
    • Export Citation
  • 5

    Kitajima K, Murakami K, Yamasaki E. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging 2009; in press.

    • Search Google Scholar
    • Export Citation
  • 6

    Lardinois D, Weder W, Hany TF. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:25002507.

    • Search Google Scholar
    • Export Citation
  • 7

    Strobel K, Heinrich S, Bhure U. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 2008;49:14081413.

    • Search Google Scholar
    • Export Citation
  • 8

    Tateishi U, Yamaguchi U, Seki K. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 2007;245:839847.

    • Search Google Scholar
    • Export Citation
  • 9

    Antoch G, Saoudi N, Kuehl H. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:43574368.

    • Search Google Scholar
    • Export Citation
  • 10

    Warburg O. The Metabolism of Tumors. New York: Richard R. Smith; 1931.

  • 11

    Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891899.

  • 12

    Kelloff GJ, Hoffman JM, Johnson B. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:27852808.

    • Search Google Scholar
    • Export Citation
  • 13

    Mankoff DA, Eary JF, Link JM. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 2007;13:34603469.

    • Search Google Scholar
    • Export Citation
  • 14

    Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004;22:42174226.

  • 15

    Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654662.

    • Search Google Scholar
    • Export Citation
  • 16

    Eary JF, O’Sullivan F, Powitan Y. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:11491154.

    • Search Google Scholar
    • Export Citation
  • 17

    Oshida M, Uno K, Suzuki M. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998;82:22272234.

    • Search Google Scholar
    • Export Citation
  • 18

    Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531540.

    • Search Google Scholar
    • Export Citation
  • 19

    Robbins RJ, Wan Q, Grewal RK. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498505.

    • Search Google Scholar
    • Export Citation
  • 20

    CMS final decision memo: Available at: https://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&id=218&. Accessed April 7, 2009.

    • Search Google Scholar
    • Export Citation
  • 21

    Hillner BE, Liu D, Coleman RE. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med 2007;48:19011908.

  • 22

    Hillner BE, Siegel BA, Liu D. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 2008;26:21552161.

    • Search Google Scholar
    • Export Citation
  • 23

    Hillner BE, Siegel BA, Shields AF. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 2008;49:19281935.

    • Search Google Scholar
    • Export Citation
  • 24

    Levine MN, Julian JA. Registries that show efficacy: good, but not good enough. J Clin Oncol 2008;26:53165319.

  • 25

    Chatterton BE, Ho Shon I, Baldey A. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 2009;36:354361.

    • Search Google Scholar
    • Export Citation
  • 26

    Scott AM, Gunawardana DH, Bartholomeusz D. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med 2008;49:15931600.

    • Search Google Scholar
    • Export Citation
  • 27

    Scott AM, Gunawardana DH, Kelley B. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med 2008;49:14511457.

    • Search Google Scholar
    • Export Citation
  • 28

    Scott AM, Gunawardana DH, Wong J. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 2009;36:347353.

    • Search Google Scholar
    • Export Citation
  • 29

    Mol BW, Lijmer JG, Evers JL, Bossuyt PM. Characteristics of good diagnostic studies. Semin Reprod Med 2003;21:1725.

  • 30

    van Tinteren H, Hoekstra OS, Smit EF. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:13881393.

    • Search Google Scholar
    • Export Citation
  • 31

    Maziak D, Darling GE, Inculet RI. A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 7502.

    • Search Google Scholar
    • Export Citation
  • 32

    Herder GJ, Kramer H, Hoekstra OS. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006;24:18001806.

    • Search Google Scholar
    • Export Citation
  • 33

    Sobhani I, Tiret E, Lebtahi R. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008;98:875880.

    • Search Google Scholar
    • Export Citation
  • 34

    van Heijl M, Omloo JM, van Berge Henegouwen MI. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys 2008;8:3.

    • Search Google Scholar
    • Export Citation
  • 35

    Shankar LK, Hoffman JM, Bacharach S. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:10591066.

    • Search Google Scholar
    • Export Citation
  • 36

    Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008;26:712720.

  • 37

    Alavi JB, Alavi A, Chawluk J. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62:10741078.

  • 38

    De Witte O, Levivier M, Violon P. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996;39:470476; discussion 476–477.

    • Search Google Scholar
    • Export Citation
  • 39

    Padma MV, Said S, Jacobs M. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227237.

  • 40

    Stupp R, Mason WP, van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987996.

  • 41

    Brandsma D, Stalpers L, Taal W. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453461.

    • Search Google Scholar
    • Export Citation
  • 42

    Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:18611867.

  • 43

    Chao ST, Suh JH, Raja S. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001;96:191197.

    • Search Google Scholar
    • Export Citation
  • 44

    Chen W, Silverman DH. Advances in evaluation of primary brain tumors. Semin Nucl Med 2008;38:240250.

  • 45

    Hustinx R, Pourdehnad M, Kaschten B, Alavi A. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005;43:3547.

    • Search Google Scholar
    • Export Citation
  • 46

    Spence AM, Muzi M, Mankoff DA. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 2004;45:16531659.

    • Search Google Scholar
    • Export Citation
  • 47

    Tsuyuguchi N, Sunada I, Iwai Y. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003;98:10561064.

    • Search Google Scholar
    • Export Citation
  • 48

    Grosu AL, Weber WA, Franz M. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:511519.

    • Search Google Scholar
    • Export Citation
  • 49

    Tralins KS, Douglas JG, Stelzer KJ. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002;43:16671673.

    • Search Google Scholar
    • Export Citation
  • 50

    Attanasi F, Belcari N, Camarda M. Experimental validation of the filtering approach for dose monitoring in proton therapy at low energy. Phys Med 2008;24:102106.

    • Search Google Scholar
    • Export Citation
  • 51

    Knopf A, Parodi K, Paganetti H. Quantitative assessment of the physical potential of proton beam range verification with PET/CT. Phys Med Biol 2008;53:41374151.

    • Search Google Scholar
    • Export Citation
  • 52

    Parodi K, Ferrari A, Sommerer F, Paganetti H. Clinical CT-based calculations of dose and positron emitter distributions in proton therapy using the FLUKA Monte Carlo code. Phys Med Biol 2007;52:33693387.

    • Search Google Scholar
    • Export Citation
  • 53

    Chen J, Cheong JH, Yun MJ. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:23832390.

    • Search Google Scholar
    • Export Citation
  • 54

    Shah MA, Yeung H, Trocola R. The characteristics and utility of FDG-PET/CT scans in patients with localized gastric cancer (GC) [abstract]. Presented at the 2007 Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando, Florida. Abstract 2.

    • Search Google Scholar
    • Export Citation
  • 55

    Yang QM, Kawamura T, Itoh H. Is PET-CT suitable for predicting lymph node status for gastric cancer? Hepatogastroenterology 2008;55:782785.

  • 56

    Yun M, Lim JS, Noh SH. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med 2005;46:15821588.

  • 57

    Flamen P, Lerut A, Van Cutsem E. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:32023210.

    • Search Google Scholar
    • Export Citation
  • 58

    van Westreenen HL, Westerterp M, Bossuyt PM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004;22:38053812.

    • Search Google Scholar
    • Export Citation
  • 59

    van Westreenen HL, Westerterp M, Sloof GW. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 2007;94:15151520.

    • Search Google Scholar
    • Export Citation
  • 60

    Westerterp M, van Westreenen HL, Reitsma JB. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology 2005;236:841851.

    • Search Google Scholar
    • Export Citation
  • 61

    Downey RJ, Akhurst T, Ilson D. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428432.

    • Search Google Scholar
    • Export Citation
  • 62

    Flamen P, Van Cutsem E, Lerut A. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361368.

    • Search Google Scholar
    • Export Citation
  • 63

    Ott K, Fink U, Becker K. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604610.

    • Search Google Scholar
    • Export Citation
  • 64

    Weber WA, Ott K, Becker K. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:30583065.

    • Search Google Scholar
    • Export Citation
  • 65

    Lordick F, Ott K, Krause BJ. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797805.

    • Search Google Scholar
    • Export Citation
  • 66

    Clinicaltrials.gov. A phase II trial of preoperative irinotecan, cisplatin and radiation in esophageal cancer. Available at: http://clinicaltrials.gov/ct/show/NCT00316862. Accessed February 9, 2009.

    • Search Google Scholar
    • Export Citation
  • 67

    Effert PJ, Bares R, Handt S. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996;155:994998.

    • Search Google Scholar
    • Export Citation
  • 68

    Hofer C, Laubenbacher C, Block T. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:3135.

    • Search Google Scholar
    • Export Citation
  • 69

    Liu IJ, Zafar MB, Lai YH. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108111.

    • Search Google Scholar
    • Export Citation
  • 70

    Kang DE, White RL Jr, Zuger JH. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004;171:18061809.

    • Search Google Scholar
    • Export Citation
  • 71

    Gofrit ON, Mishani E, Orevi M. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 2006;176:940944; discussion 944.

    • Search Google Scholar
    • Export Citation
  • 72

    Morris MJ, Akhurst T, Osman I. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913918.

    • Search Google Scholar
    • Export Citation
  • 73

    Fricke E, Machtens S, Hofmann M. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003;30:607611.

    • Search Google Scholar
    • Export Citation
  • 74

    Kao CH, Hsieh JF, Tsai SC. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000;20:21892192.

    • Search Google Scholar
    • Export Citation
  • 75

    Picchio M, Treiber U, Beer AJ. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006;47:938944.

    • Search Google Scholar
    • Export Citation
  • 76

    Drieskens O, Oyen R, Van Poppel H. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005;32:14121417.

  • 77

    Anjos DA, Etchebehere EC, Ramos CD. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007;48:764770.

    • Search Google Scholar
    • Export Citation
  • 78

    Liu IJ, Lai YH, Espiritu JI. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int 2006;77:6975.

    • Search Google Scholar
    • Export Citation
  • 79

    Safaei A, Figlin R, Hoh CK. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 2002;57:5662.

    • Search Google Scholar
    • Export Citation
  • 80

    Wu HC, Yen RF, Shen YY. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas—a preliminary report. J Cancer Res Clin Oncol 2002;128:503506.

    • Search Google Scholar
    • Export Citation
  • 81

    Majhail NS, Urbain JL, Albani JM. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003;21:39954000.

    • Search Google Scholar
    • Export Citation
  • 82

    Yen TC, Ng KK, Ma SY. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003;21:36513658.

    • Search Google Scholar
    • Export Citation
  • 83

    Lin WC, Hung YC, Yeh LS. Usefulness of (18) F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol 2003;89:7376.

    • Search Google Scholar
    • Export Citation
  • 84

    Xue F, Lin LL, Dehdashti F. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol 2006;101:147151.

    • Search Google Scholar
    • Export Citation
  • 85

    Risum S, Hogdall C, Loft A. The diagnostic value of PET/CT for primary ovarian cancer--a prospective study. Gynecol Oncol 2007;105:145149.

  • 86

    Suzuki R, Miyagi E, Takahashi N. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer 2007;17:890896.

    • Search Google Scholar
    • Export Citation
  • 87

    Chao A, Chang TC, Ng KK. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging 2006;33:3644.

  • 88

    Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007;298:22892295.

    • Search Google Scholar
    • Export Citation
  • 89

    Gold MA. PET in cervical cancer—implications for ‘staging,’ treatment planning, assessment of prognosis, and prediction of response. J Natl Compr Canc Netw 2008;6:3745.

    • Search Google Scholar
    • Export Citation
  • 90

    Yen TC, See LC, Chang TC. Defining the priority of using 18F-FDG PET for recurrent cervical cancer. J Nucl Med 2004;45:16321639.

  • 91

    Husain A, Akhurst T, Larson S. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol 2007;106:177180.

    • Search Google Scholar
    • Export Citation
  • 92

    Murakami M, Miyamoto T, Iida T. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16(Suppl 1):99107.

    • Search Google Scholar
    • Export Citation
  • 93

    Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007;105:1722.

    • Search Google Scholar
    • Export Citation
  • 94

    Simcock B, Neesham D, Quinn M. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006;103:271276.

  • 95

    Mangili G, Picchio M, Sironi S. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007;34:658666.

    • Search Google Scholar
    • Export Citation
  • 96

    Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular). Technology assessment report prepared by UAEPC for AHRQ. Available at: http://www.cms.hhs.gov/determinationprocess/downloads/id54TA.pdf. Accessed February 24, 2009.

    • Search Google Scholar
    • Export Citation
  • 97

    Schirrmeister H, Bommer M, Buck AK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:361366.

    • Search Google Scholar
    • Export Citation
  • 98

    Schirrmeister H, Buck AK, Bergmann L. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003;18:841845.

    • Search Google Scholar
    • Export Citation
  • 99

    Mileshkin L, Blum R, Seymour JF. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 2004;72:3237.

    • Search Google Scholar
    • Export Citation
  • 100

    Nanni C, Zamagni E, Farsad M. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006;33:525531.

    • Search Google Scholar
    • Export Citation
  • 101

    Breyer RJ III, Mulligan ME, Smith SE. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol 2006;35:632640.

    • Search Google Scholar
    • Export Citation
  • 102

    Fonti R, Salvatore B, Quarantelli M. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008;49:195200.

    • Search Google Scholar
    • Export Citation
  • 103

    Durie BG, Waxman AD, D’Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:14571463.

  • 104

    Bang S, Chung HW, Park SW. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006;40:923929.

    • Search Google Scholar
    • Export Citation
  • 105

    Zimny M, Bares R, Fass J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997;24:678682.

    • Search Google Scholar
    • Export Citation
  • 106

    Sperti C, Pasquali C, Decet G. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 2005;9:2228; discussion 28–29.

    • Search Google Scholar
    • Export Citation
  • 107

    Brandt KR, Charboneau JW, Stephens DH. CT- and US-guided biopsy of the pancreas. Radiology 1993;187:99104.

  • 108

    Chang KJ, Nguyen P, Erickson RA. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997;45:387393.

    • Search Google Scholar
    • Export Citation
  • 109

    Mertz HR, Sechopoulos P, Delbeke D, Leach SD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000;52:367371.

    • Search Google Scholar
    • Export Citation
  • 110

    Farma JM, Santillan AA, Melis M. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008;15:24652471.

    • Search Google Scholar
    • Export Citation
  • 111

    Heinrich S, Goerres GW, Schafer M. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005;242:235243.

    • Search Google Scholar
    • Export Citation
  • 112

    Corvera CU, Blumgart LH, Akhurst T. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008;206:5765.

    • Search Google Scholar
    • Export Citation
  • 113

    Kim JY, Kim MH, Lee TY. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008;103:11451151.

    • Search Google Scholar
    • Export Citation
  • 114

    Petrowsky H, Wildbrett P, Husarik DB. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006;45:4350.

    • Search Google Scholar
    • Export Citation
  • 115

    Rodriguez-Fernandez A, Gomez-Rio M, Llamas-Elvira JM. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg 2004;188:171175.

    • Search Google Scholar
    • Export Citation
  • 116

    Anderson CD, Rice MH, Pinson CW. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004;8:9097.

    • Search Google Scholar
    • Export Citation
  • 117

    Seo S, Hatano E, Higashi T. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 2008;143:769777.

    • Search Google Scholar
    • Export Citation
  • 118

    Park JW, Kim JH, Kim SK. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49:19121921.

    • Search Google Scholar
    • Export Citation
  • 119

    Wudel LJ Jr, Delbeke D, Morris D. The role of [18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69:117124; discussion 124–116.

    • Search Google Scholar
    • Export Citation
  • 120

    Ruf J, Lopez Hanninen E, Oettle H. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005;5:266272.

    • Search Google Scholar
    • Export Citation
  • 121

    Chen YK, Hsieh DS, Liao CS. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res 2005;25:47194725.

    • Search Google Scholar
    • Export Citation
  • 122

    Yang SH, Suh KS, Lee HW. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:16551660.

    • Search Google Scholar
    • Export Citation
  • 123

    Seo S, Hatano E, Higashi T. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007;13:427433.

    • Search Google Scholar
    • Export Citation
  • 124

    Chikamoto A, Tsuji T, Takamori H. The diagnostic efficacy of FDG-PET in the local recurrence of hilar bile duct cancer. J Hepatobiliary Pancreat Surg 2006;13:403408.

    • Search Google Scholar
    • Export Citation
  • 125

    Anderson GS, Brinkmann F, Soulen MC. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003;28:192197.

    • Search Google Scholar
    • Export Citation
  • 126

    Paudyal B, Oriuchi N, Paudyal P. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep 2007;18:14691473.

    • Search Google Scholar
    • Export Citation
  • 127

    Zhao M, Wu PH, Zeng YX. [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Ai Zheng 2005;24:11181123 [in Chinese].

    • Search Google Scholar
    • Export Citation
  • 128

    Nieweg OE, Pruim J, van Ginkel RJ. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257261.

  • 129

    Schulte M, Brecht-Krauss D, Heymer B. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000;41:16951701.

  • 130

    Franzius C, Daldrup-Link HE, Sciuk J. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001;12:479486.

    • Search Google Scholar
    • Export Citation
  • 131

    Lucas JD, O’Doherty MJ, Wong JC. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998;80:441447.

    • Search Google Scholar
    • Export Citation
  • 132

    Franzius C, Sciuk J, Daldrup-Link HE. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000;27:13051311.

    • Search Google Scholar
    • Export Citation
  • 133

    Demetri GD, von Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472480.

    • Search Google Scholar
    • Export Citation
  • 134

    Demetri GD, van Oosterom AT, Garrett CR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:13291338.

    • Search Google Scholar
    • Export Citation
  • 135

    Van den Abbeele AD. The lessons of GIST—PET and PET/CT: a new paradigm for imaging. Oncologist 2008;13(Suppl 2):813.

  • 136

    Antoch G, Kanja J, Bauer S. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45:357365.

    • Search Google Scholar
    • Export Citation
  • 137

    van den Abbeele A, Melenevsky Y, de Vries D. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST) [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 9006.

    • Search Google Scholar
    • Export Citation
  • 138

    Prior JO, Montemurro M, Orcurto MV. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009;27:439445.

    • Search Google Scholar
    • Export Citation
  • 139

    Bradley JD, Dehdashti F, Mintun MA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22:32483254.

    • Search Google Scholar
    • Export Citation
  • 140

    Brink I, Schumacher T, Mix M. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:16141620.

    • Search Google Scholar
    • Export Citation
  • 141

    Chin R Jr, McCain TW, Miller AA. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002;37:16.

    • Search Google Scholar
    • Export Citation
  • 142

    Hauber HP, Bohuslavizki KH, Lund CH. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest 2001;119:950954.

    • Search Google Scholar
    • Export Citation
  • 143

    Kamel EM, Zwahlen D, Wyss MT. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:19111917.

    • Search Google Scholar
    • Export Citation
  • 144

    Kut V, Spies W, Spies S. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007;30:4550.

    • Search Google Scholar
    • Export Citation
  • 145

    Schumacher T, Brink I, Mix M. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001;28:483488.

  • 146

    Shen YY, Shiau YC, Wang JJ. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 2002;22:12571264.

    • Search Google Scholar
    • Export Citation
  • 147

    Vinjamuri M, Craig M, Campbell-Fontaine A. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008;9:3034.

    • Search Google Scholar
    • Export Citation
  • 148

    Lee HY, Chung JK, Jeong JM. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer. Ann Nucl Med 2008;22:281286.

    • Search Google Scholar
    • Export Citation
  • 149

    Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F] FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003;30:7884.

    • Search Google Scholar
    • Export Citation
  • 150

    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:21642167.

  • 151

    Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype—papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol 2007;18:17.

    • Search Google Scholar
    • Export Citation
  • 152

    Pryma DA, Schoder H, Gonen M. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med 2006;47:12601266.

    • Search Google Scholar
    • Export Citation
  • 153

    Lowe VJ, Mullan BP, Hay ID. 18F-FDG PET of patients with Hurthle cell carcinoma. J Nucl Med 2003;44:14021406.

  • 154

    Katz SC, Shaha A. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg 2008;207:259264.

  • 155

    Gough J, Scott-Coombes D, Fausto Palazzo F. Thyroid incidentaloma: an evidence-based assessment of management strategy. World J Surg 2008;32:12641268.

    • Search Google Scholar
    • Export Citation
  • 156

    Ong SC, Schoder H, Patel SG. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007;48:501507.

    • Search Google Scholar
    • Export Citation
  • 157

    Giraudet AL, Vanel D, Leboulleux S. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007;92:41854190.

    • Search Google Scholar
    • Export Citation
  • 158

    Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007;3:112121.

    • Search Google Scholar
    • Export Citation
  • 159

    Leboulleux S, Schroeder PR, Busaidy NL. Assessment of the incremental value of recombinant TSH stimulation before FDG PET/CT imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009;94:13101316.

    • Search Google Scholar
    • Export Citation
  • 160

    Wang W, Larson SM, Fazzari M. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:11071113.

    • Search Google Scholar
    • Export Citation
  • 161

    Feine U, Lietzenmayer R, Hanke JP. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:14681472.

  • 162

    Hung MC, Wu HS, Kao CH. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res 2003;29:169175.

    • Search Google Scholar
    • Export Citation
  • 163

    Schluter B, Bohuslavizki KH, Beyer W. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42:7176.

    • Search Google Scholar
    • Export Citation
  • 164

    Bogsrud TV, Karantanis D, Nathan MA. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008;18:713719.

  • 165

    Juweid ME, Stroobants S, Hoekstra OS. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571578.

    • Search Google Scholar
    • Export Citation
  • 166

    Hillner BE, Siegel BA, Shields AF. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 2009;115:410418.

    • Search Google Scholar
    • Export Citation
  • 167

    Esthappan J, Chaudhari S, Santanam L. Prospective clinical trial of positron emission tomography/computed tomography image-guided intensity-modulated radiation therapy for cervical carcinoma with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2008;72:11341139.

    • Search Google Scholar
    • Export Citation
  • 168

    Pirotte B, Goldman S, Massager N. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 2004;101:476483.

    • Search Google Scholar
    • Export Citation
  • 169

    Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008;49(Suppl 2):64S80S.

  • 170

    Rischin D, Hicks RJ, Fisher R. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:20982104.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 368 250 19
PDF Downloads 245 206 18
EPUB Downloads 0 0 0